Searching... Searching...
  • NVP + 4.45%
  • Köp 5.34
  • Sälj 5.39
  • Senast 5.40
  • SEK

  • NEVPF +NA
  • Buy NA
  • Sell NA
  • Latest NA
  • USD

Equity research

2018-05-30

Company update by Edison:

KL1333 Ph I positive; rights issue oversubscribed


2018-03-05

Company update by Edison:

Rights issue to reach several R&D events


2017-12-14

Company update by Edison:

Two new trials and likely out-licensing in 2018


2017-11-30

Company analysis by Analysguiden:

Licensiering i sikte


2017-08-25

Company analysis by Edison:

R&D progress on track; new investor in board


2017-07-05

Company analysis by SeeThruEquity:

Update


2017-06-29

Company analysis by Edison:

Mitochondrial medicine specialist


2017-06-28

Company analysis by Analysguiden:

NeuroVive stärker handen 


2017-06-19

Company valuation report by Monocl:

NeuroVive Pharmaceutical


2017-02-16

Company analysis by BioStock:

NeuroVive Pharmaceutical


2016-12-05

Company analysis by SeeThruEquity:

Update


2016-12-02

Company analysis by Analysguiden:

Nystart lovande på sikt 


2016-09-21

Company analysis by SeeThruEquity:

Initiating Coverage


2016-09-16

Company analysis by Morningstar

Quantitative Equity Report


2016-06-13

Company analysis by Erik Penser

Clearer focus


2016-04-27

Bolagsanalys av BioStock

Analysuppdatering: NeuroVive Pharmaceutical 


2016-03-31

Bolagsanalys av Börshandlat:

Nyemission säkrar långsiktig finansiering 


2016-02-29

Bolagsanalys av Erik Penser:

Tar in nytt kapital 


2016-02-09

Bolagsanalys av, Analysguiden:

Skadeskjuten högoddsare 


 

Comments are closed.

IR Contact

Catharina Johansson

CFO

ir@neurovive.com

+46 (0) 46-275 62 21

  • Press Releases

    NeuroVive’s genetic mitochondrial disease drug candidate KL1333 mechanism of action published in scientific journal 06 July Lund, Sweden and Seoul, Korea, 6 July 2018 – NeuroVive ... Read More